antibody therapeutic. On the other hand, several pharmaceutical manufacturers have had to deal with overcapacity issues in recent years due to increased regulations on drug usage that resulted in decreasing product demand. They employed a fixed design and assumed that product demand would rapidly grow and are now left with unused manufacturing equipment. Using a flexible design can help in preventing overcapacity issues in the future. Works Cited World Preview 2016 Report. Evaluate Pharma. 2010. Eibl, and Dieter Eibl. Disposable Bioreactors (Heidelberg, Germany: Springer-Verlag, 2009), 191. Kelley, Brian. of mAb Production: The Bioprocessing Industry at “Industrialization a Crossroads.” mAbs Journal. 1:5 (Sep/Oct 2009): 443-452. Kelley, Brian. Large Scale Monoclonal Antibody Purification: The Case for “Very Conventional Unit Operations.” Biotechnology Progress. 23:5 (2007): 995-1008. Pharmaceuticals & Biotech Industry Global Report. IMAP, 2011. – Darby, Nigel. in Biological Manufacturing: How will our Industry Change “Trends in the Next 10 Years.” ASME Conference. 2008. Cacciotti, Jerry and Patrick Clinton. Annual Pharm Exec 50.” Pharmaceutical “12 Executive. Online: Basu, Prabir etc. all. of Manufacturing Costs at Pharmaceutical “Analysis Companies.”Journal of Pharmaceutical Innovation.3 (March 2008): 30-40. Sinclair, Andrew and Miriam Monge. Economic Evaluation of Single “Quantitative Use Disposables in Bioprocessing.” Biopharm Services. V06 Reichert, Janice etc. all. antibody successes in the clinic.” Nature “Monoclonal Biotechnology. 23:9 (September 2005): 1073-1078.
antibody therapeutic. On the other hand, several pharmaceutical manufacturers have had to deal with overcapacity issues in recent years due to increased regulations on drug usage that resulted in decreasing product demand. They employed a fixed design and assumed that product demand would rapidly grow and are now left with unused manufacturing equipment. Using a flexible design can help in preventing overcapacity issues in the future. Works Cited World Preview 2016 Report. Evaluate Pharma. 2010. Eibl, and Dieter Eibl. Disposable Bioreactors (Heidelberg, Germany: Springer-Verlag, 2009), 191. Kelley, Brian. “Industrialization of mAb Production: The Bioprocessing Industry at a Crossroads.” mAbs Journal. 1:5 (Sep/Oct 2009): 443-452. Kelley, Brian. “Very Large Scale Monoclonal Antibody Purification: The Case for Conventional Unit Operations.” Biotechnology Progress. 23:5 (2007): 995-1008. Pharmaceuticals & Biotech Industry – Global Report. IMAP, 2011. Darby, Nigel. “Trends in Biological Manufacturing: How will our Industry Change in the Next 10 Years.” ASME Conference. 2008. Cacciotti, Jerry and Patrick Clinton. “12 Annual Pharm Exec 50.” Pharmaceutical Executive. Online: Basu, Prabir etc. all. “Analysis of Manufacturing Costs at Pharmaceutical Companies.”Journal of Pharmaceutical Innovation.3 (March 2008): 30-40. Sinclair, Andrew and Miriam Monge. “Quantitative Economic Evaluation of Single Use Disposables in Bioprocessing.” Biopharm Services. V06 Reichert, Janice etc. all. “Monoclonal antibody successes in the clinic.” Nature Biotechnology. 23:9 (September 2005): 1073-1078.
dev_nishanth_esd71_ap_final.docx